PCO371

Igama leMchiza:

1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl))-1,3,8-triazaspiro[4.5]dec-1-en-8-yl )sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione

Ikhowudi yoncumo:

O=C1NC(C(C)(C)N1C2=CC(C)=C(CCS(=O)(N(CC3)CCC3(N=C(C4=CC=C(OC(F)(F)F )C=C4)N5)C5=O)=O)C(C)=C2)=O

Ikhowudi ye-InChi:

InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44( 41,42)36-12-10-28(11-13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30, 31)32/h5-8,15-16H,9-14H2,1-4H3,(H,33,35,39)(H,34,38,40)

Isitshixo se-InChi:

LTZJFVOUPUFOHX-UHFFFAOYSA-N

Igama elingundoqo:

PCO371; PCO-371; PCO 371

Ukunyibilika: 

Ugcino: 

Inkcazo:

I-PCO371 yi-agonist enamandla kwaye ekhethiweyo ye-PTHR1 yonyango lwe-hypoparathyroidism. Ukulawulwa komlomo kwe-PCO371 kwiigundane ze-osteopenic kukhuthaza ukwanda okukhulu kwethambo kunye nokunyuka okuncinci kwithambo. Kwiigundane ze-hypocalcemic, i-PCO371 ibuyisela amanqanaba e-serum calcium ngaphandle kokunyuswa kwe-urinary calcium, kunye nemiphumo enamandla kunye nexesha elide kune-injection ye-PTH.

Ithagethi: PTHR1